Literature DB >> 27677656

How to facilitate early diagnosis of CNS involvement in malignant lymphoma.

Agnieszka Korfel1, Martha Nowosielski2, Javier Pardo-Moreno3, Francisco Javier Penalver4, Gabriele Buda5, Hind Bennani6, Myrto Costopoulos7, Magali Le Garff-Tavernier7, Carole Soussain8, Mathias Schmid9, Jose Alberto Orfao10, Michael Glantz11.   

Abstract

INTRODUCTION: Making the diagnosis of secondary CNS involvement in lymphoma can be difficult due to unspecific signs and symptoms, limited accessibility of brain/myelon parenchyma and low sensitivity and/or specifity of imaging and cerebrospinal fluid (CSF) examination currently available. Areas covered: MRI of the total neuroaxis followed by CSF cytomorphology and flow cytometry are methods of choice when CNS lymphoma (CNSL) is suspected. To reduce the numerous pitfalls of these examinations several aspects should be considered. New CSF biomarkers might be of potential diagnostic value. Attempts to standardize response criteria are presented. Expert commentary: Diagnosing CNSL remains challenging. Until diagnostic methods combining high sensitivity with high specifity are routinely introduced, high level of awareness and optimal utilization of examinations currently available are needed to early diagnose this potentially devastating disease.

Entities:  

Keywords:  Secondary CNS lymphoma; cerebrospinal fluid cytomorphology; cerebrospinal fluid flow cytometry; meningeal; neuroaxis MRI; novel markers; parenchymal; response criteria

Mesh:

Substances:

Year:  2016        PMID: 27677656     DOI: 10.1080/17474086.2016.1242405

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  3 in total

1.  Neurological misdiagnoses of lymphoma.

Authors:  Chen Makranz; David Arkadir; Boaz Nachmias; Moshe E Gatt; Ruth Eliahou; Karine Atlan; Anat Mordechai; Netta Goldshmit; Alexander Lossos
Journal:  Neurol Sci       Date:  2020-09-24       Impact factor: 3.307

2.  CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.

Authors:  Aurelian Ungureanu; Magali Le Garff-Tavernier; Myrto Costopoulos; Timothée Parratte; Abdelmalek Brinet; Hélène Durand; Claude Gaultier; Remy Hurstel; Isabelle Alamome; François Sellal; Guido Ahle
Journal:  J Neurol       Date:  2021-02-20       Impact factor: 4.849

3.  Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification.

Authors:  Sarah Iglseder; Martha Nowosielski; Gabriel Bsteh; Armin Muigg; Johanna Heugenhauser; Elke Mayer; Astrid Grams; Günther Stockhammer; Meinhard Nevinny-Stickel
Journal:  Strahlenther Onkol       Date:  2022-03-10       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.